Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) P/E ratio
As of 25 September 2026, Solventum Corporation (SOLV) trades at a P/E ratio of 10.9×. Over the past ten years it has ranged from 6.8× (June 2024) to 36.0× (July 2025); the current reading is higher than 55% of that period. That is below the Medical Instruments & Supplies industry median of 34.2× and below the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 8.9× | (63.06%) |
| FY2024 | 24.0× | 134.03% |
| FY2023 | 10.3× | 0.00% |
| FY2022 | 10.3× | — |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 9.4× | 18.00% |
| Mar 2026 | 8.0× | (10.37%) |
| Dec 2025 | 8.9× | 6.24% |
| Sep 2025 | 8.4× | (75.99%) |
| 10 more quarters | Free account |
Against its own ten years
Low 6.8×
High 36.0×
Ten-year median
10.1×
Current reading's percentile
55
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTR Avantor, Inc. compare | n/m |
| BAX Baxter International Inc. compare | n/m |
| SOLV Solventum Corporation | 10.9× |
| COO The Cooper Companies, Inc. compare | 18.9× |
| ATR AptarGroup, Inc. compare | 22.1× |
| ALGN Align Technology, Inc. compare | 25.5× |
| WST West Pharmaceutical Services, Inc. compare | 47.1× |
| ALC Alcon compare | 49.2× |
| RGEN Repligen Corporation compare | 253× |
| Medical Instruments & Supplies industry median | 34.2× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement